Prelude Therapeutics Incorporated
$4.51
▲
0.29%
2026-04-21 08:57:00
preludetx.com
NMS: PRLD
Explore Prelude Therapeutics Incorporated stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$279.73 M
Current Price
$4.51
52W High / Low
$5.54 / $0.72
Stock P/E
—
Book Value
$0.83
Dividend Yield
—
ROCE
-118.39%
ROE
-99.45%
Face Value
—
EPS
$-1.29
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
79
Beta
0.71
Debt / Equity
25.92
Current Ratio
1.99
Quick Ratio
1.99
Forward P/E
-3.56
Price / Sales
21.13
Enterprise Value
$251.32 M
EV / EBITDA
-2.48
EV / Revenue
20.7
Rating
None
Target Price
$5.17
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lexaria Bioscience Corp. | $0.99 | — | $25.53 M | — | -443.04% | -1.55% | $1.69 / $0.46 | $0.22 |
| 2. | Curis, Inc. | $0.62 | — | $24.33 M | — | -558.61% | 2829.1% | $3.13 / $0.49 | $0.42 |
| 3. | VivoSim Labs, Inc. | $1.54 | — | $4.02 M | — | -115.61% | -51.07% | $5.3 / $1.25 | $1.7 |
| 4. | Rapport Therapeutics, Inc. | $37.14 | — | $1.9 B | — | -25.36% | -28.22% | $42.27 / $7.73 | $10.14 |
| 5. | Lexicon Pharmaceuticals, Inc. | $1.84 | — | $764.74 M | — | -29.8% | -39.72% | $1.95 / $0.49 | $0.3 |
| 6. | Nektar Therapeutics | $100.35 | — | $2.87 B | — | -57.64% | -2.18% | $109 / $7.99 | $4.41 |
| 7. | Veru Inc. | $2.43 | — | $39 M | — | -161.13% | -60.25% | $7.4 / $2.06 | $2.31 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 5.64 M | 6.5 M | 0 M | 0 M | 4 M | — |
| Operating Profit | -17.35 M | -20.42 M | -32.19 M | -34.61 M | -33.83 M | — |
| Net Profit | -16.46 M | -19.73 M | -31.23 M | -32.09 M | -28.73 M | — |
| EPS in Rs | -0.38 | -0.45 | -0.71 | -0.73 | -0.66 | -0.43 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 12.14 M | 7 M | 0 M | 0 M |
| Operating Profit | -104.57 M | -139.71 M | -132.28 M | -123.54 M |
| Net Profit | -99.5 M | -127.17 M | -121.83 M | -115.44 M |
| EPS in Rs | -2.27 | -2.91 | -2.78 | -2.64 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 141.31 M | 175.51 M | 277.67 M | 220.5 M |
| Total Liabilities | 72.68 M | 44.06 M | 40.58 M | 25.06 M |
| Equity | 68.64 M | 131.46 M | 237.09 M | 195.44 M |
| Current Assets | 105.69 M | 135.9 M | 235.59 M | 204.38 M |
| Current Liabilities | 52.99 M | 25.64 M | 21.83 M | 21.7 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -56.3 M | -102.89 M | -107.06 M | -83.73 M |
| Investing CF | 53.46 M | 90.19 M | -34.65 M | 81.69 M |
| Financing CF | 24.82 M | -0.12 M | 136.4 M | 0.81 M |
| Free CF | -56.37 M | -103.65 M | -110.58 M | -86.75 M |
| Capex | -0.07 M | -0.76 M | -3.51 M | -3.02 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -4.38% | -5.54% | — | — |
| Profit Margin % | -1816.76% | — | — | — |
| Operating Margin % | -1995.91% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1970.6% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.